Prospective observational study examines bilirubin levels to predict hyperbilirubinemia in neonates, suggesting improved risk assessment for follow-up.
Background: Jaundice is common in neonates, yet clinically significant hyperbilirubinemia may develop after early discharge. Bilirubin typically peaks between days 3 and 5; therefore, reliable predischarge biomarkers could improve risk stratification and follow-up planning. This study assessed whether cord blood total serum bilirubin (TSB) and 24-hour TSB can predict significant hyperbilirubinemia on day 5 in healthy term neonates. Methods: This hospital-based prospective observational study enrolled 200 healthy inborn term neonates (gestational age ≥ 37 weeks, birth weight ≥ 2.5 kg) and followed them from birth to day 5. Neonates with sepsis, asphyxia, intrauterine growth restriction, congenital anomalies, or ABO/Rh incompatibility were excluded. Cord bilirubin was measured at birth and venous bilirubin at 24 hours. Day-5 TSB was measured at approximately 120 hours (±6 hours). The prespecified analytic outcome for prediction was day-5 TSB ≥ 15 mg/dL. Phototherapy, when clinically required, was initiated according to the American Academy of Pediatrics (AAP) 2022 hour-specific phototherapy thresholds for infants ≥35 weeks and was recorded as a clinical management outcome. Receiver operating characteristic (ROC) analysis was used to assess discrimination and determine optimal cutoff values. Results: Using the prespecified analytic endpoint of day-5 TSB ≥15 mg/dL, 77/200 neonates (38.5%) met the study outcome. Cord bilirubin showed strong discrimination (AUC 0.893, 95% CI 0.846-0.940; p < 0.001); a cutoff of 1.75 mg/dL yielded 89.7% sensitivity and 69.9% specificity. The 24-hour bilirubin also performed well (AUC 0.880, 95% CI 0.83-0.93; p < 0.001); a cutoff of 5.80 mg/dL provided 88.0% sensitivity and 80.5% specificity, with 54.0% positive predictive value and 96.0% negative predictive value. Lower birth weight (2.5-3.0 kg) was significantly associated with the outcome (p < 0.001), whereas sex was not (p = 0.57). Conclusion: Cord bilirubin and 24-hour bilirubin both predict significant day-5 hyperbilirubinemia with high discrimination. The high negative predictive value at 24 hours supports early identification of low-risk neonates, while elevated values at either time point justify closer follow-up rather than automatic treatment. Using two early measurement time points may strengthen discharge counseling and planned surveillance; however, these cutoff values should be used as screening tools rather than treatment thresholds.
No takes yet. Share an insight, caveat, or question.
Sabbu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: